Literature DB >> 25060923

Recent progress in sodium channel modulators for pain.

Sharan K Bagal1, Mark L Chapman2, Brian E Marron3, Rebecca Prime4, R Ian Storer5, Nigel A Swain5.   

Abstract

Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Electrophysiology screening; Sodium channel drugs; Sodium channel structure; Sodium channel toxins; Voltage-gated sodium channels

Mesh：

Substances：

Year:  2014        PMID： 25060923     DOI： 10.1016/j.bmcl.2014.06.038

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  40 in total

Review 1.  Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia.

Authors:  Damian C Bell; Mark L Dallas
Journal:  Br J Pharmacol       Date:  2017-07-18       Impact factor: 8.739

Review 2.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

3.  Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Authors:  Brian A Sparling; S Yi; J Able; H Bregman; Erin F DiMauro; R S Foti; H Gao; A Guzman-Perez; H Huang; M Jarosh; T Kornecook; J Ligutti; B C Milgram; B D Moyer; B Youngblood; V L Yu; M M Weiss
Journal:  Medchemcomm       Date:  2016-12-02       Impact factor: 3.597

4.  The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.

Authors:  D C Pryde; N A Swain; P A Stupple; C W West; B Marron; C J Markworth; D Printzenhoff; Z Lin; P J Cox; R Suzuki; S McMurray; G J Waldron; C E Payne; J S Warmus; M L Chapman
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

5.  Corrigendum to "Chronic stress and peripheral pain: Evidence for distinct, region-specific changes in visceral and somatosensory pain regulatory pathways" [Exp Neurol. 2015 Nov.; 273: 301-11].

Authors:  Gen Zheng; Shuangsong Hong; John M Hayes; John W Wiley
Journal:  Exp Neurol       Date:  2016-03-08       Impact factor: 5.330

Review 6.  Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go?

Authors:  Zhi-Mei Li; Li-Xia Chen; Hua Li
Journal:  Curr Med Sci       Date:  2019-12-16

7.  Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802.

Authors:  Yue-Ming Zheng; Wan-Fu Wang; Yan-Fen Li; Yong Yu; Zhao-Bing Gao
Journal:  Acta Pharmacol Sin       Date:  2017-11-02       Impact factor: 6.150

8.  Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium channel subtypes (Nav 1.1 to Nav 1.7).

Authors:  Tadaaki Tsukamoto; Yukie Chiba; Minoru Wakamori; Tomoshi Yamada; Shunsuke Tsunogae; Yuko Cho; Ryo Sakakibara; Takuya Imazu; Shouta Tokoro; Yoshiki Satake; Masaatsu Adachi; Toshio Nishikawa; Mari Yotsu-Yamashita; Keiichi Konoki
Journal:  Br J Pharmacol       Date:  2017-09-20       Impact factor: 8.739

9.  Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Authors:  Thilo Focken; Shifeng Liu; Navjot Chahal; Maxim Dauphinais; Michael E Grimwood; Sultan Chowdhury; Ivan Hemeon; Paul Bichler; David Bogucki; Matthew Waldbrook; Girish Bankar; Luis E Sojo; Clint Young; Sophia Lin; Noah Shuart; Rainbow Kwan; Jodie Pang; Jae H Chang; Brian S Safina; Daniel P Sutherlin; J P Johnson; Christoph M Dehnhardt; Tarek S Mansour; Renata M Oballa; Charles J Cohen; C Lee Robinette
Journal:  ACS Med Chem Lett       Date:  2016-01-19       Impact factor: 4.345

10.  Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation.

Authors:  Lingxin Wang; Shannon G Zellmer; David M Printzenhoff; Neil A Castle
Journal:  Br J Pharmacol       Date:  2015-10-15       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.